PHAARMASIA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.94 INR | -0.44% |
|
-0.31% | -8.71% |
| May. 25 | Phaarmasia Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
| May. 25 | Phaarmasia Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 172M 2.06M | Sales 2023 | 275M 3.3M | Capitalization | 160M 1.92M |
|---|---|---|---|---|---|
| Net income 2022 | -15M -180K | Net income 2023 | -12M -144K | EV / Sales 2022 | 1.22 x |
| Net cash position 2022 | 551K 6.6K | Net cash position 2023 | 2.84M 34.06K | EV / Sales 2023 | 0.57 x |
| P/E ratio 2022 |
-13.6
x | P/E ratio 2023 |
-12.7
x | Employees | 13 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.44% | ||
| 1 week | -0.31% | ||
| 1 month | -13.19% | ||
| 3 months | +16.65% | ||
| 6 months | +33.36% | ||
| Current year | -8.71% |
1 week
35.20
39.70
1 month
35.2041.80
Current year
27.0146.20
1 year
22.1146.20
3 years
20.2046.20
5 years
10.3046.20
10 years
8.3050.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | - | |
Urvashi Bhatia
CMP | Compliance Officer | - | 20-01-02 |
| Director/Board Member | 61 | 04-09-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 53 | 06-02-28 | |
| Director/Board Member | 69 | 09-04-29 | |
| Director/Board Member | 61 | 04-09-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 35.94 | -0.44% | 401 |
| 24-05-30 | 36.1 | -5.00% | 325 |
| 24-05-29 | 38 | +3.12% | 239 |
| 24-05-28 | 36.85 | -2.64% | 688 |
| 24-05-27 | 37.85 | +4.99% | 2,206 |
Delayed Quote Bombay S.E., May 31, 2024 at 06:00 am EDT
More quotes
Phaarmasia Limited is an India-based company, which is primarily engaged in the manufacturing and sale of oral contraceptive pills (OCPâs). The Company manufactures and markets oral contraceptive tablets with various therapeutic dosage combinations along with iron tablets for the Ministry of Health & Family Welfare and for exports. Its product categories include hormone products and herbal products. Its hormone products include Estradiol Valerate Tablets; Medroxyprogesterone Acetate Tablets; Cabergoline Tablets; Clomiphene Citrate Tablets; Levonorgestrel Tablet; Fluoxymesterone tablets; Liothyronine Sodium tablets; Oxandrolone tablets and others. Its herbal products include Smyle Herbal Toothpaste; Smyle Cough & Sore Throat Reliver and Smyle Mouth Ulcer Gel. Its injectables include Testosterone Cypionate Injection; Methenolone Enanthate Injection; Drostanolone, Testosterone and Trenbolone Inj, and Stanozolol Cypionate Inj.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.71% | 2.94M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- PHRMASI6 Stock
